<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091428</url>
  </required_header>
  <id_info>
    <org_study_id>C14008</org_study_id>
    <nct_id>NCT01091428</nct_id>
  </id_info>
  <brief_title>MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer</brief_title>
  <official_title>Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an
      open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly
      paclitaxel in adult female patients with advanced breast cancer (Phase 1 portion only) and
      recurrent ovarian cancer (both Phase 1 and Phase 2 portions).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and tolerability of MLN8237 plus weekly paclitaxel by determining the maximum tolerated dose of MLN8237</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 1 study, to determine the recommended dose and schedule of MLN8237 and dose of paclitaxel for Phase 2 combination treatment arm</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 2 study, to assess progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Phase 1 study, to characterize effect of concomitant administration of MLN8237 on the pharmacokinetics (PK) of paclitaxel</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 1 study, to characterize the pharmacokinetics (PK) of MLN8237 administered concomitantly with paclitaxel</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 1 study, to assess best overall combined response rate in patients with recurrent ovarian cancer or breast cancer</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 2 study, to estimate overall response rate (ORR), duration of response (DOR), time to disease progression (TTP) &amp; overall survival (OS) associated w/ MLN8237 + weekly paclitaxel &amp; weekly paclitaxel alone in patients w/ recurrent ovarian cancer</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the banked tumor specimens for candidate markers of response to MLN8237 and taxanes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 2 study, to assess adverse events, serious adverse events, clinical laboratory values and vital sign measurements</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1 (MLN8237 + Paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Paclitaxel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN8237 + Paclitaxel</intervention_name>
    <description>Phase 1:
MLN8237 administered orally twice daily on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel (Days 1, 8, 15) as an intravenous infusion repeated in 28-day cycles</description>
    <arm_group_label>Arm 1 (MLN8237 + Paclitaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN8237+Paclitaxel vs. Paclitaxel alone</intervention_name>
    <description>Phase 2:
Arm 1:
MLN8237 administered orally twice daily on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel (Days 1, 8, 15) as an intravenous infusion repeated in 28-day cycles
Arm 2:
Paclitaxel will be administered as an intravenous infusion on Days 1, 8 and 15 of each 28-day cycle</description>
    <arm_group_label>Arm 1 (MLN8237 + Paclitaxel)</arm_group_label>
    <arm_group_label>Arm 2 (Paclitaxel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

          -  Female patients 18 years or older

          -  Previously treated, metastatic or locally recurrent malignancy with 1 of the following
             diagnoses, which has been confirmed histologically or cytologically: adenocarcinoma of
             the breast (Phase 1 only), recurrent epithelial ovarian, fallopian tube, or primary
             peritoneal carcinoma (Phase 1 and 2)

          -  In the Phase 1 portion of the study, patients with breast cancer must have received
             treatment with at least 1 but no more than 4 prior chemotherapy regimens not including
             regimens received in the neoadjuvant and/or adjuvant setting

          -  Patients with breast cancer must have measurable disease per Response Evaluation
             Criteria in Solid Tumors (RECIST) 1.1

          -  No antineoplastic therapy or radiotherapy within 3 weeks before enrollment (2 weeks
             for regimens with recovery expected within 7 to 14 days) and recovered from toxicities
             of prior therapy (except alopecia); the patient must have recovered from all
             treatment-related toxicities and must have evidence of PD or persistent disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate bone marrow, liver and renal function

          -  Postmenopausal at least 1 year, OR Surgically sterile, OR If childbearing potential,
             agree to 2 effective methods of nonhormonal contraception, or agree to completely
             abstain from heterosexual intercourse

          -  Able to provide written informed consent

          -  Willing to comply with scheduled visits, treatment plan, laboratory tests and other
             trial procedures

          -  Suitable venous access

        Specific Inclusion Criteria for Patients with Recurrent Ovarian, Fallopian Tube or
        Peritoneal Cancer:

          -  Prior treatments must have included a platinum and a taxane; the most recent treatment
             need not be a platinum-containing or taxane-containing regimen

          -  Disease must have recurred ≤ 12 months after discontinuation of platinum therapy

          -  Patients who previously received weekly taxane are potentially eligible, provided that
             they did not progress during therapy or within 3 months of completing therapy

          -  Patients with platinum-refractory disease, as defined by progression during primary or
             subsequent platinum-based therapy or persistent radiographic disease after primary or
             subsequent platinum-based therapy, will be included

          -  Patients must have measurable disease in target lesions or assessable disease (defined
             by CA-125 per protocol), and disease progression per Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1 or modified Gynecologic Cancer Intergroup (GCIG)
             CA-125 criteria

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Prior treatment with an Aurora A-targeted agent (including MLN8237)

          -  Treatment with clinically significant enzyme inducers within 14 days prior to the
             first dose of MLN8237 and during the study

          -  Treatment with more than 4 cytotoxic chemotherapy regimens in the metastatic setting;
             prior therapy cannot include more than 2 prior taxane-containing regimens

          -  Known hypersensitivity to Cremophor® EL, paclitaxel or its components

          -  Prior history of ≥ Grade 2 neurotoxicity or any toxicity requiring discontinuation
             from taxane chemotherapy that is not resolved to ≤ Grade 1

          -  Comorbid or unresolved toxicity that would preclude administration of weekly
             paclitaxel

          -  Primary central nervous system malignancy or carcinomatous meningitis

          -  Symptomatic brain metastasis

          -  Inability to swallow oral medications or maintain a fast

          -  History of hemorrhagic or thrombotic cerebrovascular event in past 12 months

          -  Surgery within 3 weeks before study enrollment and not fully recovered

          -  Diagnosis or treatment of another malignancy within 2 years preceding first dose of
             MLN8237 and have any evidence of residual disease except nonmelanoma skin cancer or in
             situ malignancy completely resected

          -  Pregnant or lactating

          -  Serious illness that could interfere with protocol completion

          -  Investigational treatment 21 days prior to first dose of MLN8237

          -  Prior allogeneic bone marrow or organ transplantation

          -  Infection requiring systemic antibiotic therapy within 14 days prior to first dose of
             MLN8237

          -  Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C

          -  Radiotherapy to &gt; 25% bone marrow or whole pelvic radiotherapy

          -  Requirement for constant administration of proton pump inhibitor, H2 antagonist, or
             pancreatic enzymes. Intermittent uses of antacids of H2 antagonists are allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <disposition_first_submitted>February 8, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 8, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 9, 2017</disposition_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RECIST: Response Evaluation Criteria in Solid Tumors</keyword>
  <keyword>OC: Ovarian Cancer</keyword>
  <keyword>GCIG: Gynecologic Cancer Intergroup</keyword>
  <keyword>Breast carcinoma (Phase 1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 21, 2018</submitted>
    <returned>March 21, 2018</returned>
    <submitted>May 1, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

